U.S. markets closed

Plus Therapeutics, Inc. (PSTV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5400-0.0300 (-1.17%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close2.5700
Open2.5300
Bid2.4800 x 1100
Ask2.5700 x 1200
Day's Range2.4700 - 2.5500
52 Week Range1.7300 - 5.4200
Volume286,755
Avg. Volume1,238,192
Market Cap53.61M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)-30.6160
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.81
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
    GlobeNewswire

    Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial

    AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECT™ trial, which is evaluating the Company’s lead investigational drug, Rhenium NanoLiposome (RNL™), in patients with recurrent gl

  • Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
    GlobeNewswire

    Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

    AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021. The poster presentation is titled, “A two-part, Phase I study of Rhenium-186 Nanoliposomes (186RNL) delivered by convection enhanced delivery (CED) for recurrent

  • Plus Therapeutics to Participate in BIO Digital Conference
    GlobeNewswire

    Plus Therapeutics to Participate in BIO Digital Conference

    AUSTIN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021. The Company’s presentation will be made available through the BIO Digital Conference website and available on demand to registered participants during the conference